News

Formac will use its proprietary technology platform as a starting point for the in-house development of improved delivery forms of generics and branded drugs of which the patent

CTS-1027 significantly reduced liver damage following oral administration in four different preclinical models of liver injury. CTS-1027 markedly reduced aminotransferase (ALT) activity and improved survival and liver histology

The investigational new drug application (IND) acceptance will permit Metastatix to commence Phase I clinical studies in the US to determine the safety and tolerability of MSX-122 for

The trial also showed evidence that the hearts of the patients that received the therapy showed less cardiac remodeling (an increase in the size of the heart that

The study results showed that patients receiving Locteron experienced side effects that were less frequent and less severe than those previously reported in clinical trials for the currently

The sub-study was conducted in subjects defined by the Framingham risk assessment tool as having less than two or two or more risk factors (RFs) and either thinner

Under the terms of the agreement, $7.5 million will be immediately received by the company with an additional $2.5 million to become available, if the company receives FDA

The pharmacokinetic and pharmacodynamic analysis, conducted by the University of Tennessee Health Science Center, showed that SCH 530348 (TRA), a potent thrombin receptor antagonist, demonstrated sustained, dose-dependent, specific

Under an existing agreement, DSM currently offers FloraGLO brand lutein products made with crystalline lutein supplied by Kemin. Under the terms of the new global agreement, Kemin will